Back to today’s briefing

Story perspectives

Combination Therapy Shows Promise Against Liver Disease

10/14/2025

34 7

Summary

Story summary

Researchers at the University of Barcelona report that combining pemafibrate and telmisartan may reverse metabolic dysfunction-associated steatotic liver disease by reducing liver fat.
The findings were published in Pharmacological Research.
The evidence comes from animal models, including rats and zebrafish.
The researchers say the approach could lower cardiovascular risks.
Human trials are needed to confirm safety and efficacy.

1 of 1

Story summary

Researchers at the University of Barcelona report that combining pemafibrate and telmisartan may reverse metabolic dysfunction-associated steatotic liver disease by reducing liver fat.
The findings were published in Pharmacological Research.
The evidence comes from animal models, including rats and zebrafish.
The researchers say the approach could lower cardiovascular risks.
Human trials are needed to confirm safety and efficacy.